We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Idera Pharmaceuticals Inc | NASDAQ:IDRA | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.425 | 0.432 | 0.48 | 0 | 01:00:00 |
FORM 3
| Washington, D.C. 20549 |
OMB APPROVAL
OMB Number: 3235-0104 Estimated average burden hours per response... 0.5 |
| |
1. Name and Address of Reporting Person * Pillar Invest Corp |
2. Date of Event Requiring Statement (MM/DD/YYYY)
| 3. Issuer Name and Ticker or Trading Symbol Aceragen, Inc. [ACGN] |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below) | ||
5. If Amendment, Date Original Filed(MM/DD/YYYY) | 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person _X_ Form filed by More than One Reporting Person |
Table I - Non-Derivative Securities Beneficially Owned | |||
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 355247 | I | By Pillar Partners Foundation, L.P. (1) |
Common Stock | 135540 | I | By Pillar Pharmaceuticals 6, L.P (1) |
Common Stock | 170712 | I | By Abude Umari (1) |
Common Stock | 1547 | I | By Youssef El Zein (1) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) | ||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Warrants | 7/13/2020 | 7/13/2023 | Common Stock | 162601 (2) | $0.01 | I | By Pillar Partners Foundation, L.P. (1) |
Warrants | 12/11/2020 | 12/11/2023 | Common Stock | 35687 (2) | $0.01 | I | By Pillar Partners Foundation, L.P. (1) |
Warrants | 12/11/2020 | 12/11/2023 | Common Stock | 45114 (2) | $0.01 | I | By Pillar Pharmaceuticals 6, L.P. (1) |
Reporting Owners | |||||
Reporting Owner Name / Address | |||||
Director | 10% Owner | Officer | Other | ||
Pillar Invest Corp C/O STUARTS CORPORATE SERVICES LTD. KENSINGTON HOUSE, 69 DR. ROY'S DRIVE GEORGETOWN, GRAND CAYMAN, E9 KY1-1104 | X | ||||
Pillar Partners Foundation, L.P. C/O STUARTS CORPORATE SERVICES LTD. KENSINGTON HOUSE, 69 DR. ROY'S DRIVE GEORGETOWN, GRAND CAYMAN, E9 KY1-1104 | X | ||||
Pillar Pharmaceuticals 6, L.P. C/O STUARTS CORPORATE SERVICES LTD. KENSINGTON HOUSE, 69 DR. ROY'S DRIVE GEORGETOWN, GRAND CAYMAN, E9 KY1-1104 | X | ||||
Umari Abude C/O STUARTS CORPORATE SERVICES LTD. KENSINGTON HOUSE, 69 DR. ROY'S DRIVE GEORGETOWN, GRAND CAYMAN, E9 KY1-1104 | X | ||||
ZEIN YOUSSEF EL C/O STUARTS CORPORATE SERVICES LTD. KENSINGTON HOUSE, 69 DR. ROY'S DRIVE GEORGETOWN, GRAND CAYMAN, E9 KY1-1104 | X |
Signatures | ||
Pillar Invest Corporation, /s/ Youssef El Zein, Authorized Person | 6/23/2023 | |
**Signature of Reporting Person | Date | |
Pillar Partners Foundation, L.P., /s/ Youssef El Zein, Authorized Person | 6/23/2023 | |
**Signature of Reporting Person | Date | |
Pillar Pharmaceuticals, 6, L.P., /s/ Youssef El Zein, Authorized Person | 6/23/2023 | |
**Signature of Reporting Person | Date | |
/s/ Abude Umari | 6/23/2023 | |
**Signature of Reporting Person | Date | |
/s/ Youssef El Zein | 6/23/2023 | |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1 Year Idera Pharmaceuticals Chart |
1 Month Idera Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions